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Background: Using the UK Cystic Fibrosis Database, we analysed the health of the UK CF paediatric population (UKPP) in terms of their
biographical, clinical and infection status and compared outcomes with the US, French and Australasian CF Registries.
Methods: UKPP data were collected for 2,673 patients aged less than 18 years in 2001 and used as a reference base for comparison with the
most recent equivalent CF Registry reports.
Results: Although differences exist between National CF Registries, all record similar demographic factors and key outcomes. Where
plausible comparisons can be made, we report that the UKPP had the oldest median age (15.0 years), the Australasian population had the
lowest median age at diagnosis (1.8 months). Approximately, double the expected number of UKPP patients (23% and 19%, respectively) fall
below the 10th centile for height and weight with similar outcomes in Australasia. UKPP and French populations had similar proportions
with FEV1 >80% predicted (53% and 54%, respectively).
Conclusion: Each Registry’s data systems have developed independently providing a first step towards international comparisons.
Standardisation of data collection criteria and definition for national CF Registries is required and we propose a standardised minimum data
set, which would facilitate data integration as part of a global Registry for CF.
D 2005 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Clinical database; Cystic fibrosis; Registry; Standardisation; Outcomes.1. Introduction
Cystic Fibrosis (CF) is the commonest potentially
lethal autosomal recessive disease in Caucasians. How-
ever, the health of individuals within a given CF
population will be governed by the interaction between
environmental factors such as different health care
systems and clinical protocols [3] and their profile of
genetic mutations [4]. Many countries have developed
their own National Registries, following the formative1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2005.01.001
i This work has been presented in two poster presentations at the 26th
European Cystic Fibrosis Conference held in Belfast, Northern Ireland in
June 2003 [1,2].
* Corresponding author. Tel.: +44 1382 632179; fax: +44 1382 632597.
E-mail address: j.d.mccormick@dundee.ac.uk (J. McCormick).impulse from the Canadian Patient Data Registry
established in the mid 1960s [5]. These have led to a
greater understanding of disease epidemiology and
helped highlight important associations in disease pro-
gression [6].
Differences in genetics and environment occur across
continents and childhood death is now too infrequent to be
used as an outcome. The aim of this study was to use the
UK Cystic Fibrosis Database (UKCFD) to compare
biographical, clinical and microbiological outcomes of the
UK paediatric CF population with respect to the equivalent
data reported from the US, French and Australasian CF
Registries. While some useful comparisons can be made
between the different CF populations, we propose the
collection of minimum standard data fields to facilitate
further future comparisons.4 (2005) 115 – 122ed by Elsevier B.V. All rights reserved.
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The UKCFD receives data from around 95% of specialist
CF Centres and smaller clinics, as recently described [7]. A
unique patient identifier is assigned to each patient follow-
ing registration and submission of an initial patient
biography to facilitate patient tracking across CF centres.
These Fregistered_ patients are then flagged as Factive_
patients following submission of an annual clinical data
return (Fig. 1). The gap between the registered and active
patients in Fig. 1 results from many factors: firstly, poorly
staffed clinics outside the specialist CF centres are often
unable to return clinical data even though their patients have
undergone the one-off registration process, secondly, there
is an approximate 2 year lead-time between the number of
patients with complete clinical data compared with the
number of registered patients (see Fig. 9 in Ref. [7]) and
thirdly, resourcing difficulties within CF centres lead to
delayed returns. All CF Registries record similar demo-
graphic factors and key outcomes and we have concentrated
on three quantitative outcomes: height, weight and pulmo-
nary function and a qualitative marker predictive of severeRegistered Pa
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Fig. 1. Relationship of the Fregistered_ and Factive_ paediatric populations. The age
numbers shown above columns).disease: microbiological infection. Evidence of infection
was accepted as the presence of the organism on at least one
occasion whereas three or more isolates in a single year
were regarded as evidence of chronic infection. Recent
suggestions for changes to this definition were not available
at the design stage of this work [8]. UKCFD data were
analysed on 2673 Factive_ patients aged less than 18 years
old in 2001 (Fig. 1) referred to as the UK paediatric patients
(UKPP). Their outcomes were compared across continents
with three equivalent paediatric populations in North
America, Europe and the Southern Hemisphere, respectively
within the US [9], French [10] and Australasian [11] CF
Registries.
The 2001 UKCFD data were compared with the most
recent international CF Registry reports at that time.
Although, we are cognisant of the important issues concern-
ing data quality, selection bias and control of plausibility of
data within Registries, these are outside the scope of this
manuscript but are discussed later with reference to the
plausibility of comparing outcomes between Registries.
Within the UKCFD, computerised plausibility checks and
manual measures are employed in error correction and rangetients = 6739 
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measures are in place in the US Registry (Bruce Marshall,
CFF, USA—personal communication). However, differences
in data collection do exist and examples are given below. For
the French and Australasian Registries, all non-biographical
data compared for this study were recorded annually. Micro-
biology data from the French, Australasian and US Registries
were recorded as per the UK on an ‘‘ever cultured in the
previous 12 months’’ basis. Mean values for height, weight,
body mass index (BMI) centiles and FEV1% predicted were
calculated for each UK patient. Height, weight and FEV1
recorded in the French Registry were those at the last visit or
hospitalisation in the year 2000, while the highest FEV1 in the
year was recorded in the Australasian Registry. The US
Registry records the occasion with the highest pulmonary
function test results, height and/or weight (all obtained at the
same clinic visit) for each quarter of the year. This may be
relevant because daily intra-individual variation in lung
function has been observed in CF patients, with poorer
measurements recorded during acute exacerbations [12,13].
However, the difference betweenmean recordings over a year
and an annual highest recording has not been established. In
the clinical experience of the authors, this can amount to 20%
predicted FEV1. Clearly, categorical data quality for compar-
ison between Registries can be more readily assured and will
be less prone to variation than the collection and calculation
of continuous data. Although we are not able to offer robust
data plausibility and integrity from CF Registry publications
other than our own, each Registries’ output will be subject to
the scrutiny and rigours of the Registry users.
Statistical analysis was performed using MINITAB
version 13.1 (Minitab Inc, State College, Pennsylvania,
USA), Excel 97 (Microsoft) and SPSS for Windows version
11.5 (SPSS Inc., Chicago, IL, USA). Graphical representa-Fig. 2. (a) Height centiles for 2563 UKPP patients (data unknown on 110 patie
(patient numbers shown above columns). (b) Box plot of height z-scores with 5ttions are presented using SigmaPlot (SigmaPlot for Win-
dows version 4.01; SPSS Inc., Chicago, IL, USA).
Differences between Registries were compared using the
Mann–Whitney test (non-Gaussian distributed data), pro-
portions analysis and chi-squared analysis [14]. All p values
are two-sided.3. Results
Fig. 1 shows that the UKCFD had 6739 registered (adult
and paediatric) patients in 2001. This represents greater than
85% of the estimated UK CF population, projected to be
7910 in 2001 [15]). Within this 6739 Fregistered_ popula-
tion, 4689 were Factive_ having had an annual review in the
preceding 12 months. This Factive_ population (median age
15 years; median age at diagnosis 4 months) contained 2673
Factive_ paediatric patients (PP) who formed a representative
proportion of the 3945 Fregistered_ PP by comparison of
median age and genetic profile (not shown). There was a
small but significant difference between the percentage of
DF508 homozygous patients in the Fregistered_ and Factive_
PP (55% versus 58%, respectively, p =0.02). This possibly
reflects a greater tendency towards Factive_ status amongst
#F508/#F508 PP due to the increased severity of their
disease [16]. However, as the proportions of #F508/other
mutations were similar, this small excess in homozygous
#F508 could still be a chance variation. The possible
reasons for a registered patient not being included in the
UKPP include shared care patients registered by a Specialist
CF Centre but receiving clinical care at their local hospitals
(with data not recorded for the UKCFD), patients who fail to
receive an annual review, or patients who may be in transit
between hospitals during the year in question.nts) compared against standard Tanner and Whitehouse UK growth charts
h and 95th percentile shown as outliers.
Fig. 3. a) Weight centiles for 2564 UKPP patients (data unknown on 109 patients) compared against standard Tanner and Whitehouse UK growth charts
(patient numbers shown above columns). b) Box plot of weight z-score with 5th and 95th percentile shown as outliers.
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mortality is well recognised [17–19], and our analysis of
height and weight centiles (Figs. 2 and 3) demonstrated that
approximately double the expected number of children
(23% and 19%, respectively) lie below the 10th centiles.
With respect to pulmonary status (Fig. 4), almost half (47%)
of the UKPP had an FEV1% predicted of <80%.
Table 1 shows the prevalence of bacterial airway
infection in the UKPP stratified by age with the averaged
prevalence shown in the last column. UKPP under 2 yearsFig. 4. a) Percentage of UKPP patients aged 6–18 years classified by FEV1% pred
patients in this age group. b) Box plots showing the FEV1% predicted by age grof age are routinely treated with long-term flucloxacillin to
prevent infection with Staphylococcus aureus, [20,21] and
16% of these youngest patients have cultured S. aureus on at
least one occasion. However, no patients had chronic S.
aureus infection in this age group. In older age groups, the
prevalence of chronic infection with S. aureus rose steeply
until puberty. This contrasts with our finding that 6.8% of
under 2-year-olds were chronically colonised with Pseudo-
monas aeruginosa, although this represents only a quarter of
the children who had grown P. aeruginosa on at least oneicted centiles. Spirometry data were collected on 1949 patients of the 2036
oup with 5th and 95th percentile shown as outliers.
Table 1
Prevalence of common respiratory pathogens in the UKPP
0–2 years 3–5 years 6–8 years 9–11 years 12–14 years 15–17 years Total<18 years
% P. aeruginosa (% chronic infection) 25.6 (6.8) 28.9 (10.0) 35.5 (20.6) 44.3 (26.7) 59.0 (42.7) 67.8 (54.9) 45.8 (29.5)
% S. aureus (% chronic infection) 16.0 (0.0) 22.0 (8.1) 30.3 (13.2) 42.0 (19.9) 49.8 (26.0) 42.5 (23.3.) 36.3 (17.0)
% B. complex 0.0 0.0 1.8 3.2 3.5 5.0 2.5
% H. influenzae 31.5 33.5 27.1 28.4 18.5 14.3 24.7
% Aspergillus 0.0 2.4 6.4 11.4 16.3 16.2 10.0
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complex) were low, although there may be ascertainment
bias through under-reporting as case identification is
dependent on the proficiency of laboratory practices [22].
At present, the UKCFD does not record data on the nine
genomovars included in the B. complex [23]. Haemophilus
influenzae was recorded in over 30% of the UKPP less than
2 years of age although this prevalence fell with age to less
than 15% of UKPP aged 15–17.
Having defined some key demographic and clinical
outcomes in the UKPP, the similarities and differences with
the US, French and Australasian Registries are discussed in
the next Section (Tables 2 and 3).4. Discussion
We have described the biographical, anthropometric and
infection status of paediatric CF patients in the UK for 2001
using the UKCFD. These UKPP was compared with three
paediatric CF populations reported by the US [9], French
[10] and Australasian [11] Registries. These were chosen to
provide a pragmatic geographic spread and to illustrate the
requirements for making valid international comparisons.
The UKCFD had the highest coverage of the four
Registries analysed. Comparative analysis of coverage data
indicated that each Registry was differentially representative
of their respective total estimated population. The US
population (of 280 million) had 22301 CF patients
registered with the US Registry [9]. The coverage of US
CF patients was estimated at 75% in 1993 [6]. The UK has
around one fifth of the US population and the UKPP has
approximately one fifth of the number of CF patients when
compared to the US. The French Registry estimates patientTable 2
Comparison of UK, US, French and Australasian CF populations
UK
Adult and paediatric patient population size 4689
Mean age in years 16.9
Median age in years 15.0
Mean age at diagnosis in months 2.5
Median age in diagnosis in months 4
Percentage diagnosed by 1 year of age 67
Number of paediatric patients (% of total population) 2673 (5
Percentage of paediatric population with height <10th centile 23
Percentage of paediatric population with weight <10th centile 19
Percentage of paediatric population with BMI <10th centile 12coverage to be between 43–59% [10], and whilst the
Australasian report does not indicate a specific figure and
they acknowledge deficiencies in their adult patient cover-
age [11] due to data unavailability from some clinics (Dr.
Scott Bell, Australasian Cystic Fibrosis Data Registry—
personal communication). However, the ‘‘core’’ demo-
graphic and diagnostic data for registered Australasian
patients is more comprehensive than treatment and follow-
up data [11]. This discrepancy is similar to Fregistered_ and
Factive_ patients in the UKPP.
Table 2 characterises each CF Registry population. The
median age in the French and Australasian reports were
lower than the 13.0 and 13.8 years attained in the UK and
US, respectively. This may reflect ascertainment bias due to
a lower coverage of the population. In the UK population,
67% of patients were diagnosed by 12 months of age, which
is significantly lower than the 70% in the US ( p <0.01),
Australasian ( p<0.05) and the 73% French values
( p<0.01) [9–11]. In the Australasian report, 94.3% of
new patients in 2000 were diagnosed before 6 months of
age, but only 70% of these were diagnosed through the
neonatal screening programme [11]. Therefore, screening
affected the median age at diagnosis as illustrated by
comparing the Australasian population (1.8 months) with
populations without full national screening (US—6 months,
UK—4 months, France—4 months). Twenty percent of UK
infants are already screened in restricted regional pro-
grammes with smaller proportions in the US and France.
These observed differences in median age and age at
diagnosis between countries may also be influenced by
multiple factors other than screening. These may include
national differences in paediatric surveillance systems,
different data collection protocols across National Registries
and incomplete coverage of Registry data for patientsUS French Australasian
22301 3388 2507
16.9 14.9 15.3
14.8 13.0 13.8
3.1 2.9 1.8
6 4 1.8
70 73 70
7.0) 13671 (61.3) 2226 (65.7) 1647 (65.7)
No data No data 18
No data No data 16
No data No data 17
Table 3
Prevalence rates of microbiological infection (UK versus US, France and
Australasia)
P. aeruginosa S. aureus B. complex H. influenzae
UK v US
Age 0–5 years 28 v 30 20** v 47 0 v 1 33** v 26
Age 6–10 years 37* v 42 35** v 50 2 v 2 27** v 22
Age 11–14 years 62 v 63 46** v 53 4 v 4 19** v 13
UK v France
Age 0–4 years 28* v 21 19** v 50 0 v 0 32** v 49
Age 5–9 years 35* v 28 32** v 63 1 v 2 29** v 52
Age 10–14 years 53** v 44 47** v 64 4 v 3 22** v 39
Age 15–19 years 69** v 54 45** v 60 6 v 4 13** v 27
UK v Australasia
Age 0–5 years 28** v 9 19** v 30 0 v 2 32** v 22
Age 5–17 years 50** v 22 40 v 42 3* v 5 23** v 12
Statistical significance=p <0.05=*p <0.01=**using proportions analysis.
Candida or Aspergillus infection data not shown as not available from all
four Registries. Comparisons were made between the UK with France;
Aspergillus, age 0–4 (1* v 3), age 5–9 (6** v 11), age 10–14 (15 v 17),
age 15–19 (15** v 22) and Candida, age 0–4 (25** v 15), age 5–9 (18 v
18), age 10–14 (21 v21), age 15–19 (20* v 25).
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because it is presently controversial whether age at
diagnosis is related to outcome [24].
Most clinical decisions in CF patient care are based on
the interpretation of longitudinal trends in nutritional status,
pulmonary function [25] and surveillance of microbiological
infection. Even the apparently quantitative data on height,
weight or pulmonary function are dependent on the use of
appropriate reference equations [26]. But Registry reports
do not always declare their specific reference equations for
calculating height, weight and BMI centiles. These should
be based on local populations to prevent the introduction of
systematic bias (the reference equation used to calculate
height, weight and BMI in the Australasian report was based
on US reference data [11]). While the US report did not list
BMI data, the French reported gender-specific mean BMI
plotted against age. The methods of calculating FEV1%
predicted were referenced in the French and Australasian
reports (but not the US) and were based on figures that may
not reflect their respective populations [26,27]. Reference
populations will also vary between continents and races
according to nutritional status [28]. Fifty-four percent of the
French PP and 53% of the UKPP had FEV1% predicted
>80% (Fnormal_ lung function). It is reported that 37% of
the Australasian population have Fnormal_ lung function,
but their definition of Fnormal_ is not included. Comparison
of US pulmonary function data with the French and
Australasian reports was not possible because the US report
uses the criterion of FEV1% predicted >90%, whilst the
others use >80%. Forty-two percent of the US population
had FEV1% predicted >90% and the equivalent UKPP
proportion is much lower at 33%.
One parameter that should be readily comparable
between Registries is the prevalence of common respiratorytract microbiological pathogens (Table 3), but many
difficulties remain. The acquisition of chronic P. aeruginosa
is gradual and can lead to a slow deterioration in the
patient’s respiratory status, but remains a major factor in
subsequent morbidity and mortality [29]. Some databases
report single isolates of P. aeruginosa based on a single or
multiple sampling throughout the year, but prevalence may
be dependent on the frequency of sampling (i.e. patient
contact with their CF team) [8]. The prevalence rates for P.
aeruginosa were similar in the UKPP and US, but
considerably higher than the rates in the French or Austral-
asian populations. Differences in data definition and
collection may have influenced this apparent difference
[8]. We propose that documenting mucoid status as a
surrogate for chronic infection may be simpler. Prevalence
of infection with S. aureus increased with age in the UKPP,
although this prevalence was significantly lower compared
with equivalent US, French or Australasian data. This may
represent the UK national policy to start oral prophylactic
flucloxacillin in newly diagnosed UK CF infants [21].
Although the prevalence rates of patients isolating B.
complex are low, our estimates suggest this organism leads
to the segregation of 1 in 20 CF adolescents (aged 15–17
years) in the UK which has implications for longer-term
psychological well-being [30]. Prevalence rates of B.
complex are important because of its potentially trans-
missible nature and its impact on survival [31]. Prevalence
was similar between reports, though significantly higher in
the Australasian Registry than the UKPP in the 5–17 age
group, though in neither case did this rise above 5%.
Although it is the commonest pathogen in CF during early
childhood, rates of H. influenzae decreased with age in all
populations. This may be explained by two factors: firstly,
microbiology laboratories may only report what they regard
as the primary pathogenic organism, which is less likely to
be H. influenzae once the prevalence of S. aureus and P.
aeruginosa increases (Professor J. Govan, Division of
Medical Microbiology, University of Edinburgh—personal
communication); secondly, cough swabs rather than sputum
samples are more readily collected from younger infants
who cannot yet expectorate and these could culture H.
influenzae from the upper airway, which may or may not
reflect lower airway infection [26,32]. The French Registry
reported a significantly higher prevalence of H. influenzae
at all ages compared with the UKPP, although the UKPP
had significantly higher prevalence rates at all ages
compared with the US and Australasian reports (Table 3).
Whether the French prevalence reflects different treatment
and reporting practice is unknown. Clearly, uniformity of
data reporting would facilitate interpretation of these
observed ‘‘differences’’, allowing the effect of different
national management strategies to be further explored.
Without standardised microbiological practice, this goal is
likely to remain elusive.
The consequence of the individual development of each
National Registry System has been an evolution of data
Table 4
Suggested common paediatric data for National CF Registries
Number and gender of patients.
Genotypes/CFTR mutations.
Mode of diagnosis of all new patients.
Height, weight and BMI Z-scores, and FEV1% predicted calculated using
the appropriate declared reference population and age-appropriate
equations.
Microbiological prevalence rates.
Routine therapy.
Complications e.g. CFRD, transplants and deaths.
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the needs and demands of each Registry’s CF community.
At present, the Registries are of great value for comparisons
within their individual populations, but present difficulties
for comparisons between populations. This formulates the
limitations on the control of data plausibility and leads to
our case for a universal data collection strategy to facilitate
future national comparisons. The functioning of the UKCFD
requires an accurate definition of specific clinical outcomes
in the UKPP and identification of areas where practice could
be improved if resources permit. Having identified trends in
the data between national databases we report a number of
significant problems. There will be basic differences in the
composition of the national CF populations in terms of
ethnicity, genotype and screening [33,34]. There are also
likely to be systematic differences in data capture and
patient coverage by the different national databases, and
variations in how clinical data is recorded on these patients.
A very important factor relates to differences in laboratory
practice in isolating and reporting pathogenic organisms.
Agreement must be reached on the definition of chronic
microbiological infection across Registries [8]. Differences
in recording practice for spirometry data may account for
other variations, although the use of mean data over 12
months can overcome some of these problems. Most
modern National Registries have only collected data for a
few years, therefore longitudinal inferences can currently
only be made using cross-sectional data. However, one of
the longest running projects is the Canadian Patient Data
Registry that has registered over 3400 patients
(www.ccff.ca, accessed 01/01/05). These pioneering efforts
have been a major influence on the development of other
Registries and has reported on survival determinants and
growth status and is regarded as an exemplar of Registry
practice [5,35]. Finally, differences in the format of the data
presentation, including the omission of paediatric specific
data, reduce the opportunity for comprehensive CF pop-
ulation comparisons. Considerable work has been done by
the board of the European CF Registry towards specifying a
standard EU CF Registry that will address these challenges.
We outline in Table 4 our pragmatic proposal for common
paediatric data, which would facilitate participation and
initiate progress towards International Registry compatibil-
ity. This is envisaged as a two-stage process: all countries
would contribute the essential demographics, whilst those
countries in a position to contribute clinical data would
provide these desirable fields in addition. This would
require work towards defining national reference popula-
tions and age-appropriate formulae for nutritional and lung
function data. Large International Registries (e.g. heart and
lung transplantation [36,37]) have made successful compar-
isons of outcomes, and this should be a worthwhile goal for
the CF Registries.
In conclusion, the development of national cystic
fibrosis databases has enabled this comparison of the
UKPP with the US, French and Australasian populationson selected key clinical outcomes. However, we have
highlighted the limitations of comparing current national
CF reports and recommend urgent standardisation of data
collection between national CF Registries to facilitate
greater understanding from intercontinental CF population
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